Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)

Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors

The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) when given in combination with intravenous docetaxel in cancer patients with advanced solid tumors.

Inclusion:

• Male or Female
• Measurable or evaluable disease
• No more than 2 prior chemotherapy regimens.
• Age greater than or equal to 18.
• Karnofsky Performance Status greater than or equal to 70%.
• Meets protocol requirements for specified laboratory values.
• No manifestations of a malabsorption syndrome.
• Written informed consent and cooperation of patient
• Appropriate use of effective contraception if of child-bearing potential.

Exclusion:

• Acute or chronic leukemia or multiple myeloma.
• Evidence of 2 or more active malignancies, expect for in situ or adequately treated basal or squamous cell skin cancer.